Prolonged diagnostic latency can follow vague fatigue, back pain, and breathing issues, reinforcing the need for persistent ...

Explore the evolving approach to cancer treatment, emphasizing personalized care and active surveillance over aggressive ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include: Continuous vs. fixed-duration therapy: A debate on ...

Among patients with MCL still on study in January 2025, 35.3% reported improved MCL-related symptoms, while 5.9% reported ...

Margaret Krackeler, MD, discusses real-world data supporting the switch from ibrutinib to zanubrutinib for chronic lymphocytic leukemia.

Justin C. Frankel, P.C., represented a client with Chronic Lymphocytic Leukemia whose long-term disability benefits ...

First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that ...

Several potentially practice-changing phase 3 trials alongside promising results in emerging strategies in chronic lymphocytic leukemia (CLL) presented at the 2025 American Society of Hematology ...

For many, it represents the worst day of their life: The day they receive a cancer diagnosis. Hearing the words ring from a physician’s mouth. Having the world fade away. The mind spinning with the ...

Terry Evans is in a paid partnership with Lilly and has been compensated for his time. Like many parents back in the 1990s, Terry Evans of Huntington Beach, Calif., was wrapped up in his job and ...

Studies show that sphingosine kinase 2 (SPHK2) is overexpressed in venetoclax-resistant cancer cells and that SPHK2 inhibition may reduce T-cell-induced activation and proliferation of ...